JS-K enhances chemosensitivity of prostate cancer cells to Taxol via reactive oxygen species activation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

1. The synergistic efficacy of lupeol and enzalutamide potentiates anticancer activity, inducing apoptosis and cell cycle arrest in breast cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026
   Article
2. Relationship between oxidative stress and nuclear factor-erythroid-2-related factor 2 signaling in diabetic cardiomyopathy (Review).Experimental and therapeutic medicine · 2021
   Review
3. Exogenous NO induces apoptosis of hepatocellular carcinoma cells via positive p38/JNK signaling pathway and negative ERK signaling pathways.Molecular and cellular biochemistry · 2021
   Article
4. A review of the relatively complex mechanism of JS-K induced apoptosis in cancer cells.Translational cancer research · 2019
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as